Advertisement

Investigational New Drugs

, Volume 19, Issue 2, pp 155–162 | Cite as

Oral Delivery of Taxanes

  • Mirte M. Malingré
  • Jos H. Beijnen
  • Jan H.M. Schellens
Article

Abstract

Oral treatment with cytotoxic agents is tobe preferred as this administration routeis convenient to patients, reducesadministration costs and facilitates theuse of more chronic treatment regimens. Forthe taxanes paclitaxel and docetaxel,however, low oral bioavailability haslimited development of treatment by theoral route. Preclinical studies with mdr1aP-glycoprotein knock-out mice, which lackfunctional P-glycoprotein activity in thegut, have shown significant bioavailabilityof orally administered paclitaxel.Additional studies in wild-type micerevealed good bioavailability after oraladministration when paclitaxel was combinedwith P-glycoprotein blockers such ascyclosporin A or the structurally relatedcompound SDZ PSC 833. Based on theextensive preclinical research, thefeasibility of oral administration ofpaclitaxel and docetaxel in cancer patientswas recently demonstrated in our Institute.Co-administration of cyclosporin A stronglyenhanced the oral bioavailability of bothpaclitaxel and docetaxel. For docetaxel incombination with cyclosporin A an oralbioavailability of 90% was achieved withan interpatient variability similar to thatafter intravenous drug administration; forpaclitaxel the oral bioavailability isestimated at approximately 50%. The safety of the oralroute for both taxanes is good. A phase IIstudy of weekly oral docetaxel incombination with cyclosporin A is currentlyongoing.

paclitaxel docetaxel oral administration bioavailability P-glycoprotein cytochrome P450 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Demario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557–2567, 1998PubMedGoogle Scholar
  2. 2.
    Meerum Terwogt JM, Schellens JHM, Ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treatment Rev 25: 83–101, 1999Google Scholar
  3. 3.
    Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115, 1997PubMedGoogle Scholar
  4. 4.
    Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S, Toloudis P, Georgoulias V: Treatment of non-small cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21: 505–508, 1998PubMedGoogle Scholar
  5. 5.
    Bardelmeijer HA, Van Tellingen O, Schellens JHM, Beijnen JH: The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest New Drugs 18: 231–241, 2000PubMedGoogle Scholar
  6. 6.
    Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004–1014, 1995PubMedGoogle Scholar
  7. 7.
    Huizing MT, Sewberath Misser VH, Pieters RC, Ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Invest 13: 381–4–4, 1995Google Scholar
  8. 8.
    Fujita H, Okamoto M, Takao A, Mase H, Kojima H: Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood levels. Gan to Kagaku Ryoho 21: 653–658, 1994PubMedGoogle Scholar
  9. 9.
    Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ: Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34: 465–471, 1994PubMedGoogle Scholar
  10. 10.
    Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, Mol CAAM, Van der Valk MA, Robanus-Maandag EC, Te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491–502, 1994CrossRefPubMedGoogle Scholar
  11. 11.
    Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, Van Deemter L, Smit JJM, Van der Valk MA, Voordouw AC, Spits H, Van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycloproteins. Proc Natl Acad Sci USA 94: 4028–4033, 1997PubMedGoogle Scholar
  12. 12.
    Borst P, Schinkel AH: Mice with disrupted P-glycoprotein genes. In: Gupta S and Tsuruo T (eds) Multidrug Resistance in Cancer Cells. John Wiley & Sons Ltd, Chichester, 1996, pp 345–356Google Scholar
  13. 13.
    Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152–162, 1976PubMedGoogle Scholar
  14. 14.
    Endicott JA, Ling V: The biochemistry of P-glycoproteinmediated multidrug resistance. Annu Rev Biochem 58: 137–171, 1989CrossRefPubMedGoogle Scholar
  15. 15.
    Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427, 1993CrossRefPubMedGoogle Scholar
  16. 16.
    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735–7738, 1987PubMedGoogle Scholar
  17. 17.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman JJ, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269, 1987PubMedGoogle Scholar
  18. 18.
    Van Asperen J, Mayer U, Van Tellingen O, Beijnen JH: The pharmacological role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86: 881–884, 1997PubMedGoogle Scholar
  19. 19.
    Van Asperen J, Van Tellingen O, Beijnen JH: The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37: 429–435, 1998PubMedGoogle Scholar
  20. 20.
    Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P: Human (MDR1) and mouse (mdr1, mdr3) Pglycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34: 32–39, 1995PubMedGoogle Scholar
  21. 21.
    Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60: 289–299, 1993PubMedGoogle Scholar
  22. 22.
    Borst P, Schinkel AH:What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 32A: 985–990, 1996CrossRefPubMedGoogle Scholar
  23. 23.
    Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031–2035, 1997PubMedGoogle Scholar
  24. 24.
    Van Asperen J, Van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH: Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76: 1181–1183, 1997PubMedGoogle Scholar
  25. 25.
    Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112–2115, 1996PubMedGoogle Scholar
  26. 26.
    Shet MS, Fisher CW, Holmans PL, Estabrook RW: Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 90: 11748–11752, 1993PubMedGoogle Scholar
  27. 27.
    Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM: Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026–4035, 1994PubMedGoogle Scholar
  28. 28.
    Van Asperen J, Van Tellingen O, Van der Valk MA, Rozenhart M, Beijnen JH: Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 4:2293–2297, 1998PubMedGoogle Scholar
  29. 29.
    Meerum Terwogt JM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin A enables oral therapy with paclitaxel. Lancet 352: 285, 1998Google Scholar
  30. 30.
    Meerum Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, Schellens JHM: Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5: 3379–3384, 1999PubMedGoogle Scholar
  31. 31.
    Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol 13: 180–190, 1995PubMedGoogle Scholar
  32. 32.
    Huizing MT, Giaccone G, Van Warmerdam LJC, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, Van Zandwijk N, Koolen MG, Ten Bokkel Huinink WW, Van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer. J Clin Oncol 15: 317–329, 1997PubMedGoogle Scholar
  33. 33.
    Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430–2436, 1997PubMedGoogle Scholar
  34. 34.
    Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH: Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a Pglycoprotein. Br J Cancer 79: 108–113, 1999PubMedGoogle Scholar
  35. 35.
    Schellens JHM, Meerum Terwogt JM, Ten Bokkel Huinink WW, Rosing H, Van Tellingen O, Swart M, Duchin KL, Beijnen JH: Cyclosporin A (CsA) strongly enhances oral bioavailability of paclitaxel (pac) in cancer patients (abstract). Proc Am Soc Clin Oncol 17: 186a, 1998Google Scholar
  36. 36.
    Malingré MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, Van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst, Schellens JHM: Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18: 2468–2475, 2000PubMedGoogle Scholar
  37. 37.
    Malingré MM, Meerum Terwogt JM, Schellens JHM, Duchin KL, Rosing H, Beijnen JH: Clinical pharmacology of oral paclitaxel in a dose-escalating study (abstract). Br J Clin Pharmacol, in pressGoogle Scholar
  38. 38.
    Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH: Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374–377, 1993PubMedGoogle Scholar
  39. 39.
    McKeage JH, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR, Judson IR: A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451–458, 1995PubMedGoogle Scholar
  40. 40.
    Nannan Panday VR, Huizing MT, Ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997Google Scholar
  41. 41.
    Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 8: 1263–1268, 1990PubMedGoogle Scholar
  42. 42.
    Dye D, Watkins J: Suspected anaphylactic reaction to Cremophor EL diluent. Ann Pharmacother 28: S11-S14, 1994PubMedGoogle Scholar
  43. 43.
    Duchin KL, Smith DC, Bertoli L, Weisfeld L: Oral absorption of Paxene (paclitaxel) following cyclosporin A in cancer patients (abstract). Proc Am Soc Clin Oncol 17: 239a, 1998Google Scholar
  44. 44.
    Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH: Tissue distribution, metabolism and excretion of paclitaxel in mice. Anti-Cancer Drugs 7: 78–86, 1996PubMedGoogle Scholar
  45. 45.
    Sparreboom A, Van Zuylen L, Brouwer E, Loos WJ, De Bruijn P, Gelderblom h, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454–1457, 1999PubMedGoogle Scholar
  46. 46.
    Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo)-nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335, 1999PubMedGoogle Scholar
  47. 47.
    Malingré MM, Schellens JHM, Van Tellingen O, Rosing H, Koopman FJ, Duchin K, Ten Bokkel Huinink WW, Swart M, Beijnen JH: Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after intravenous administration. Anti-Cancer Drugs 11: 813–820, 2000PubMedGoogle Scholar
  48. 48.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM: A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol, in pressGoogle Scholar
  49. 49.
    Huizing MT, Keung ACF, Rosing H, Van der Kuij V, Ten Bokkel Huinink WW, Mandjes I, Dubbelman AC, Pinedo HM, Beijnen JH: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127–2135, 1993PubMedGoogle Scholar
  50. 50.
    Richel DJ, Malingré MM, Ten Bokkel Huinink WW, Rosing H, Van Tellingen O, Swart M, Beijnen JH, Schellens JHM: Cyclosporin A strongly enhances the oral bioavailability of docetaxel in cancer patients (abstract). Proc Am Soc Clin Oncol 18: 201a, 1999Google Scholar
  51. 51.
    Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JHM: Coadministration of cyclosporin A strongly enhances the oral bioavailability of docetaxel. J Clin Oncol, in pressGoogle Scholar
  52. 52.
    Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164–2168, 1998PubMedGoogle Scholar
  53. 53.
    Löffler TM, Freund W, Dröge C: Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17: 113a, 1998Google Scholar
  54. 54.
    Climent MA, Ruiz A, Llombart-Cussac A, Fernandez-Martos C, Poveda A, Dorta J, Guillem V:Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol 18: 119a, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Mirte M. Malingré
    • 1
    • 2
  • Jos H. Beijnen
    • 1
    • 2
    • 3
  • Jan H.M. Schellens
    • 1
    • 3
  1. 1.Department of Medical OncologyThe Netherlands Cancer Institute/Antoni van Leeuwenhoek HospitalThe Netherlands
  2. 2.Department of Pharmacy and PharmacologyThe Netherlands Cancer Institute/Slotervaart HospitalAmsterdamThe Netherlands
  3. 3.Division of Drug Toxicology, Faculty of PharmacyUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations